Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity.

Ibrahim TS, Sheha TA, Abo-Dya NE, AlAwadh MA, Alhakamy NA, Abdel-Samii ZK, Panda SS, Abuo-Rahma GEA, Mohamed MFA.

Bioorg Chem. 2020 Mar 30;99:103797. doi: 10.1016/j.bioorg.2020.103797. [Epub ahead of print]

PMID:
32247939
2.

Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients: A protocol for systematic review and network meta-analysis using a generalized pairwise modeling methodology.

Danjuma MI, Mohamed MFH, ElShafei MN, Fatima H, Shokri SA, Mohamed S, Abubeker IY, Kartha A, Elzouki AN, Mohamedali MGH, Mahgboub Y, Bidmos M.

Medicine (Baltimore). 2020 Apr;99(14):e19679. doi: 10.1097/MD.0000000000019679.

3.

Molecular Typing, Antibiogram and PCR-RFLP Based Detection of Aeromonas hydrophila Complex Isolated from Oreochromis niloticus.

Algammal AM, Mohamed MF, Tawfiek BA, Hozzein WN, El Kazzaz WM, Mabrok M.

Pathogens. 2020 Mar 22;9(3). pii: E238. doi: 10.3390/pathogens9030238.

4.

Inclusion of Adolescents With Adults in Phase 3 Clinical Trials: Overview of the Current State and a Call for Action.

Mohamed MF, Rakhmanina N, Hassan HE.

J Clin Pharmacol. 2020 Mar 2. doi: 10.1002/jcph.1591. [Epub ahead of print] No abstract available.

PMID:
32119133
5.

Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety.

Al-Sanea MM, Gotina L, Mohamed MF, Grace Thomas Parambi D, Gomaa HAM, Mathew B, Youssif BGM, Alharbi KS, Elsayed ZM, Abdelgawad MA, Eldehna WM.

Drug Des Devel Ther. 2020 Feb 4;14:497-508. doi: 10.2147/DDDT.S237957. eCollection 2020.

6.

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.

Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J.

Gastroenterology. 2020 Feb 7. pii: S0016-5085(20)30167-0. doi: 10.1053/j.gastro.2020.01.047. [Epub ahead of print]

7.

Synthesis, Cytotoxicity and Docking Simulation of Novel Annulated Dihydroisoquinoline Heterocycles.

Saleh FM, Hassaneen HM, Mohamed MF, Mohamed YS.

Mini Rev Med Chem. 2020 Jan 29. doi: 10.2174/1389557520666200130104632. [Epub ahead of print]

PMID:
32000650
8.

Screening for Latent Tuberculosis among Healthcare Workers in an Egyptian Hospital Using Tuberculin Skin Test and QuantiFERON-TB Gold In-Tube Test.

Anwar MM, Ahmed DM, Elareed HR, Abdel-Latif RA, Sheemy MS, Kamel NM, Mohamed MF.

Indian J Occup Environ Med. 2019 Sep-Dec;23(3):106-111. doi: 10.4103/ijoem.IJOEM_184_19. Epub 2019 Dec 16.

9.

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication.

Mohamed MF, Klünder B, Othman AA.

Clin Pharmacokinet. 2019 Dec 23. doi: 10.1007/s40262-019-00855-0. [Epub ahead of print] Review.

PMID:
31867699
10.

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.

Guttman-Yassky E, Thaçi D, Pangan AL, Hong HC, Papp KA, Reich K, Beck LA, Mohamed MF, Othman AA, Anderson JK, Gu Y, Teixeira HD, Silverberg JI.

J Allergy Clin Immunol. 2020 Mar;145(3):877-884. doi: 10.1016/j.jaci.2019.11.025. Epub 2019 Nov 29.

11.

Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.

Nader A, Stodtmann S, Friedel A, Mohamed MF, Othman AA.

J Clin Pharmacol. 2020 Apr;60(4):528-539. doi: 10.1002/jcph.1550. Epub 2019 Nov 7.

PMID:
31701537
12.

Immunostimulants in respiratory diseases: focus on Pidotimod.

Puggioni F, Alves-Correia M, Mohamed MF, Stomeo N, Mager R, Marinoni M, Racca F, Paoletti G, Varricchi G, Giorgis V, Melioli G, Canonica GW, Heffler E.

Multidiscip Respir Med. 2019 Nov 4;14:31. doi: 10.1186/s40248-019-0195-2. eCollection 2019. Review.

13.

Molecular Docking Study, Cytotoxicity, Cell Cycle Arrest and Apoptotic Induction of Novel Chalcones Incorporating Thiadiazolyl Isoquinoline in Cervical Cancer.

Tantawy MA, Sroor FM, Mohamed MF, El-Naggar ME, Saleh FM, Hassaneen HM, Abdelhamid IA.

Anticancer Agents Med Chem. 2019 Oct 24. doi: 10.2174/1871520619666191024121116. [Epub ahead of print]

PMID:
31696811
14.

Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation.

Mohamed MF, Trueman S, Othman AA, Han JH, Ju TR, Marroum P.

AAPS J. 2019 Oct 25;21(6):108. doi: 10.1208/s12248-019-0378-y.

15.

Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis.

Nader A, Mohamed MF, Winzenborg I, Doelger E, Noertersheuser P, Pangan AL, Othman AA.

Clin Pharmacol Ther. 2020 Apr;107(4):994-1003. doi: 10.1002/cpt.1671. Epub 2019 Nov 30.

PMID:
31610021
16.

Exposure-Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended-Release Formulation.

Mohamed MF, Klünder B, Lacerda AP, Othman AA.

Clin Pharmacol Ther. 2020 Mar;107(3):639-649. doi: 10.1002/cpt.1668. Epub 2019 Nov 22.

17.

Acute psychosis and concurrent rhabdomyolysis unveiling diagnosis of hypothyroidism.

Mohamed MF, Mahgoub AB, Sardar S, Elzouki AN.

BMJ Case Rep. 2019 Oct 5;12(10). pii: e231579. doi: 10.1136/bcr-2019-231579.

PMID:
31586959
18.
19.

Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail.

Mohamed MF, Feng T, Enejosa JV, Fisniku O, Othman AA.

J Clin Pharmacol. 2020 Jan;60(1):86-95. doi: 10.1002/jcph.1496. Epub 2019 Aug 5.

20.

Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors.

Mohamed MFA, Youssif BGM, Shaykoon MSA, Abdelrahman MH, Elsadek BEM, Aboraia AS, Abuo-Rahma GEA.

Bioorg Chem. 2019 Oct;91:103127. doi: 10.1016/j.bioorg.2019.103127. Epub 2019 Jul 18.

PMID:
31374527
21.

Mean platelet volume as a predictor of pulmonary hypertension in patients with stable COPD.

Mohamed MF, Ali A, Abbas A, Awad MS, Gouda M, Sediq AM.

Int J Chron Obstruct Pulmon Dis. 2019 May 23;14:1099-1108. doi: 10.2147/COPD.S176413. eCollection 2019.

22.

Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection.

Mohamed MF, Klünder B, Camp HS, Othman AA.

Clin Pharmacol Ther. 2019 Dec;106(6):1319-1327. doi: 10.1002/cpt.1543. Epub 2019 Aug 23.

23.

EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules.

Abou-Zied HA, Youssif BGM, Mohamed MFA, Hayallah AM, Abdel-Aziz M.

Bioorg Chem. 2019 Aug;89:102997. doi: 10.1016/j.bioorg.2019.102997. Epub 2019 May 22.

PMID:
31136902
24.

Statin-Induced Rhabdomyolysis, Acute Kidney Injury, and Hepatitis Leading to Death.

Mohamed MFH, Salameh OK, Saeed AAM.

Am J Case Rep. 2019 May 18;20:709-712. doi: 10.12659/AJCR.914707.

25.

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.

Trueman S, Mohamed MF, Feng T, Lacerda AP, Marbury T, Othman AA.

J Clin Pharmacol. 2019 Sep;59(9):1188-1194. doi: 10.1002/jcph.1414. Epub 2019 Apr 11.

26.

Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review.

Al Raiisi F, Stewart D, Fernandez-Llimos F, Salgado TM, Mohamed MF, Cunningham S.

Int J Clin Pharm. 2019 Jun;41(3):630-666. doi: 10.1007/s11096-019-00816-4. Epub 2019 Apr 9.

27.

Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.

Klünder B, Mittapalli RK, Mohamed MF, Friedel A, Noertersheuser P, Othman AA.

Clin Pharmacokinet. 2019 Aug;58(8):1045-1058. doi: 10.1007/s40262-019-00739-3.

28.

Novel aryl carboximidamide and 3-aryl-1,2,4-oxadiazole analogues of naproxen as dual selective COX-2/15-LOX inhibitors: Design, synthesis and docking studies.

Youssif BGM, Mohamed MFA, Al-Sanea MM, Moustafa AH, Abdelhamid AA, Gomaa HAM.

Bioorg Chem. 2019 Apr;85:577-584. doi: 10.1016/j.bioorg.2019.02.043. Epub 2019 Feb 20.

PMID:
30878890
30.

Biological Activity, Apoptotic Induction and Cell Cycle Arrest of New Hydrazonoyl Halides Derivatives.

Mohamed MF, Hassaneen HM, Elzayat EM, El-Hallouty SM, El-Manawaty M, Saleh FM, Mohamed Y, El-Zohiry D, Fahmy G, Abdelaal N, Hassanin N, Hossam N.

Anticancer Agents Med Chem. 2019;19(9):1141-1149. doi: 10.2174/1871520619666190306123658.

PMID:
30843494
31.

Transition-State Interactions in a Promiscuous Enzyme: Sulfate and Phosphate Monoester Hydrolysis by Pseudomonas aeruginosa Arylsulfatase.

van Loo B, Berry R, Boonyuen U, Mohamed MF, Golicnik M, Hengge AC, Hollfelder F.

Biochemistry. 2019 Mar 12;58(10):1363-1378. doi: 10.1021/acs.biochem.8b00996. Epub 2019 Feb 27.

PMID:
30810299
32.

Management of recalcitrant corneal ulcers with dry processed amniotic membrane.

Bhatia J, Narayanadas B, Varghese M, Mansi MA, Mohamed MF, Gad AAH, Bhatia N.

Oman J Ophthalmol. 2019 Jan-Apr;12(1):68-69. doi: 10.4103/ojo.OJO_95_2018. No abstract available.

33.

Moringa peregrina Leaves Extracts Induce Apoptosis and Cell Cycle Arrest of Hepatocellular Carcinoma.

Mansour M, Mohamed MF, Elhalwagi A, El-Itriby HA, Shawki HH, Abdelhamid IA.

Biomed Res Int. 2019 Jan 1;2019:2698570. doi: 10.1155/2019/2698570. eCollection 2019.

34.

Recent Synthetic Approaches and Biological Evaluations of Amino Hexahydroquinolines and Their Spirocyclic Structures.

Abdelmoniem AM, Mohamed MF, Abdelmoniem DM, Ghozlan SAS, Abdelhamid IA.

Anticancer Agents Med Chem. 2019;19(7):875-915. doi: 10.2174/1871520619666190131140436. Review.

PMID:
30706793
35.

Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics.

Mohamed MF, Trueman S, Feng T, Anderson J, Marbury TC, Othman AA.

J Clin Pharmacol. 2019 Jun;59(6):856-862. doi: 10.1002/jcph.1375. Epub 2019 Jan 11.

36.

Impact of correction of anemia in end-stage renal disease patients on cerebral circulation and cognitive functions.

Shaker AM, Mohamed OM, Mohamed MF, El-Khashaba SO.

Saudi J Kidney Dis Transpl. 2018 Nov-Dec;29(6):1333-1341. doi: 10.4103/1319-2442.248306.

37.

The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects.

Mohamed MF, Trueman S, Feng T, Friedman A, Othman AA.

J Clin Pharmacol. 2019 Apr;59(4):510-516. doi: 10.1002/jcph.1350. Epub 2018 Nov 30.

38.

Balancing Specificity and Promiscuity in Enzyme Evolution: Multidimensional Activity Transitions in the Alkaline Phosphatase Superfamily.

van Loo B, Bayer CD, Fischer G, Jonas S, Valkov E, Mohamed MF, Vorobieva A, Dutruel C, Hyvönen M, Hollfelder F.

J Am Chem Soc. 2019 Jan 9;141(1):370-387. doi: 10.1021/jacs.8b10290. Epub 2018 Dec 20.

PMID:
30497259
39.

Molecular Studies on Novel Antitumor Bis 1,4-Dihydropyridine Derivatives Against Lung Carcinoma and their Limited Side Effects on Normal Melanocytes.

Mohamed MF, Ibrahim NS, Elwahy AHM, Abdelhamid IA.

Anticancer Agents Med Chem. 2018;18(15):2156-2168. doi: 10.2174/1871520618666181019095007.

PMID:
30338746
40.

Synthesis, Cytotoxicity, Antimicrobial and Docking Simulation of Novel Pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[3,4-c] pyrimidine Derivatives.

Hassaneen HM, Saleh FM, Abdallah TA, Mohamed MF, Mohamed YS, Awad EM, Abdelhamid IA.

Mini Rev Med Chem. 2019;19(8):657-670. doi: 10.2174/1389557518666181017162459.

PMID:
30332953
41.

Correction to "Dual Targeting of Intracellular Pathogenic Bacteria with a Cleavable Conjugate of Kanamycin and an Antibacterial Cell-Penetrating Peptide".

Brezden A, Mohamed MF, Nepal M, Harwood JS, Kuriakose J, Seleem MN, Chmielewski J.

J Am Chem Soc. 2018 Oct 10;140(40):13125-13126. doi: 10.1021/jacs.8b09906. Epub 2018 Sep 28. No abstract available.

PMID:
30264564
42.

Are Clinical Therapeutic Protein-Drug Interaction Studies Needed When Disease Modification Is Driving the Potential Interaction?

Pang Y, Rosebraugh MR, Freise KJ, Parikh A, Mohamed MF.

J Clin Pharmacol. 2018 Oct;58(10):1371-1372. doi: 10.1002/jcph.1290. Epub 2018 Aug 21. No abstract available.

PMID:
30129669
43.

Evolutionary repurposing of a sulfatase: A new Michaelis complex leads to efficient transition state charge offset.

Miton CM, Jonas S, Fischer G, Duarte F, Mohamed MF, van Loo B, Kintses B, Kamerlin SCL, Tokuriki N, Hyvönen M, Hollfelder F.

Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):E7293-E7302. doi: 10.1073/pnas.1607817115. Epub 2018 Jul 16.

44.

A Library Approach to Cationic Amphiphilic Polyproline Helices that Target Intracellular Pathogenic Bacteria.

Nepal M, Mohamed MF, Blade R, Eldesouky HE, N Anderson T, Seleem MN, Chmielewski J.

ACS Infect Dis. 2018 Sep 14;4(9):1300-1305. doi: 10.1021/acsinfecdis.8b00124. Epub 2018 Jul 13.

PMID:
29979033
45.

Novel pyrrol-2(3H)-ones and pyridazin-3(2H)-ones carrying quinoline scaffold as anti-proliferative tubulin polymerization inhibitors.

Abdelbaset MS, Abuo-Rahma GEA, Abdelrahman MH, Ramadan M, Youssif BGM, Bukhari SNA, Mohamed MFA, Abdel-Aziz M.

Bioorg Chem. 2018 Oct;80:151-163. doi: 10.1016/j.bioorg.2018.06.003. Epub 2018 Jun 5.

PMID:
29920422
46.

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.

Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, Zhou Y, Mohamed MF, Meerwein S, Pangan AL.

Lancet. 2018 Jun 23;391(10139):2513-2524. doi: 10.1016/S0140-6736(18)31116-4. Epub 2018 Jun 18.

PMID:
29908670
47.

Grafting polymerization of acrylic acid onto chitosan-cellulose hybrid and application of the graft as highly efficient ligand for elimination of water hardness: Validation of high selectivity in presence of interfering ions.

Mohamed MF, Zhou X, Ibrahim HS, Ammar NS, Essawy HA.

Int J Biol Macromol. 2018 Sep;116:530-536. doi: 10.1016/j.ijbiomac.2018.05.062. Epub 2018 May 17.

PMID:
29763700
48.

Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials.

Mohamed MF, Zeng J, Marroum PJ, Song IH, Othman AA.

Clin Pharmacol Drug Dev. 2019 Feb;8(2):208-216. doi: 10.1002/cpdd.462. Epub 2018 Apr 24.

49.

Design, synthesis, mechanistic and histopathological studies of small-molecules of novel indole-2-carboxamides and pyrazino[1,2-a]indol-1(2H)-ones as potential anticancer agents effecting the reactive oxygen species production.

Youssif BGM, Abdelrahman MH, Abdelazeem AH, Abdelgawad MA, Ibrahim HM, Salem OIA, Mohamed MFA, Treambleau L, Bukhari SNA.

Eur J Med Chem. 2018 Feb 25;146:260-273. doi: 10.1016/j.ejmech.2018.01.042. Epub 2018 Jan 31.

PMID:
29407956
50.

Cytotoxicity, molecular modeling, cell cycle arrest, and apoptotic induction induced by novel tetrahydro-[1,2,4]triazolo[3,4-a]isoquinoline chalcones.

Mohamed MF, Hassaneen HM, Abdelhamid IA.

Eur J Med Chem. 2018 Jan 1;143:532-541. doi: 10.1016/j.ejmech.2017.11.045. Epub 2017 Nov 21.

PMID:
29207336

Supplemental Content

Loading ...
Support Center